ProMetic and Blue Blood sign manufacturing deal

Guest Contributor
June 18, 2007

Montreal's ProMetic BioTherapeutics Inc has entered a strategic alliance with Taiwan's Blue Blood Biotech Corp to develop drugs derived from human plasma and utilizing ProMetic's proprietary manufacturing process. Blue Blood and ProMetic BioTherapeutics, a subsidiary of ProMetic Life Sciences Inc, will share in revenues projected at $50 million annually. Production will initially focus on hyperimmune cytomega-lovirus aimed at the Taiwanese and Southeast Asian markets....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.